Skip to content
Study details
Enrolling now

Semaglutide Therapy for Alcohol Reduction (STAR)

National Institute on Drug Abuse (NIDA)
NCT IDNCT06015893ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

52

Study length

about 7.2 years

Ages

18–110

Locations

1 site in MD

What this study is about

This trial is testing if Semaglutide, a medication, can help people with alcohol use disorder reduce their drinking. Participants will receive either Semaglutide or a placebo shot weekly and undergo various tests to monitor their progress.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Control
  • 2.Take Semaglutide

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Oral

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

semaglutide (GLP-1 agonist; stimulates insulin release)

Drug routes

oral (Oral Tablet)

Endpoints

Primary: Determine the safety and tolerability of semaglutide in individuals with AUD.

Secondary: Determine whether semaglutide reduces blood Phosphatidylethanol (PEth) levels as a biomarker of alcohol use.

Body systems

Psychiatry / Mental Health